Bristol Heart Institute, University of Bristol, School of Clinical Sciences, United Kingdom.
Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2346-2355.e6. doi: 10.1016/j.jtcvs.2018.02.012. Epub 2018 Feb 13.
The Arterial Revascularization Trial has been designed to answer the question whether the use of bilateral internal thoracic arteries can improve 10-year outcomes when compared with single internal thoracic arteries. In the Arterial Revascularization Trial, a significant proportion of patients initially allocated to bilateral internal thoracic arteries received other conduit strategies. We sought to investigate the incidence and clinical implication of bilateral internal thoracic artery graft conversion in the Arterial Revascularization Trial.
Among patients enrolled in the Arterial Revascularization Trial (n = 3102), we excluded those allocated to single internal thoracic arteries (n = 1554), those who did not undergo surgery (n = 16), and those who underwent operation but withdrew after randomization (n = 7). Propensity score matching was used to compare converted versus nonconverted bilateral internal thoracic artery groups.
A total of 1525 patients were operated with the intention to receive bilateral internal thoracic artery grafting. Of those, 233 (15.3%) were converted to other conduit selection strategies. Incidence of conversion largely varied across 131 participating surgeons (from 0% to 100%). The most common reason for bilateral internal thoracic artery graft conversion was the evidence of at least 1 internal thoracic artery that was not suitable, which was reported in 77 cases. Patients with intraoperative bilateral internal thoracic artery graft conversion received a lower number of grafts (2.95 ± 0.84 vs 3.21 ± 0.74; P < .001). However, the hospital mortality rate was comparable to that of those who did not require bilateral internal thoracic artery graft conversion (0% vs 1.6%; P = .1), as well as the incidence of major complications. At 5 years, we found a nonsignificant excess of deaths (11.9% vs 8.4%; P = .1) and major adverse events (17.1% 13.2%; P = .1) mainly driven by an excess of revascularization in patients requiring conversion.
The incidence of intraoperative bilateral internal thoracic artery graft conversion is not infrequent. Bilateral internal thoracic artery graft conversion is not associated with increased operative morbidity, but its effect on late outcomes remains uncertain.
动脉血管重建试验旨在回答当与单一内乳动脉相比时,使用双侧内乳动脉是否能改善 10 年的结果。在动脉血管重建试验中,相当一部分最初被分配到双侧内乳动脉的患者接受了其他移植物策略。我们试图研究在动脉血管重建试验中双侧内乳动脉移植物转换的发生率和临床意义。
在动脉血管重建试验(n=3102)中,我们排除了被分配到单一内乳动脉的患者(n=1554)、未接受手术的患者(n=16)和随机分组后退出手术的患者(n=7)。采用倾向评分匹配比较转换组与非转换组的双侧内乳动脉。
共有 1525 名患者计划接受双侧内乳动脉移植术。其中,233 名(15.3%)被转换为其他移植物选择策略。转换的发生率在 131 名参与手术的医生中差异很大(从 0%到 100%)。双侧内乳动脉移植物转换的最常见原因是至少有 1 条内乳动脉不适合,这种情况在 77 例中报告。术中双侧内乳动脉移植物转换的患者接受的移植物数量较少(2.95±0.84 与 3.21±0.74;P<.001)。然而,医院死亡率与无需双侧内乳动脉移植物转换的患者相似(0%与 1.6%;P=.1),主要并发症的发生率也相似。5 年后,我们发现死亡(11.9%与 8.4%;P=.1)和主要不良事件(17.1%与 13.2%;P=.1)的发生率略有增加,主要是由于需要转换的患者的再血管化增加。
术中双侧内乳动脉移植物转换的发生率并不少见。双侧内乳动脉移植物转换与手术发病率增加无关,但对晚期结果的影响仍不确定。